A. Cassidy

Physical function, employment and quality of life in end-stage renal disease.

C. Blake, M. Codd, Y. O’Meara, 2000, Journal of nephrology.

Sarcopenia and change in body composition following maximal androgen suppression with abiraterone in men with castration-resistant prostate cancer

N. Tunariu, D. Mukherji, D. Olmos, 2013, British Journal of Cancer.

Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer.

M. Dowsett, R. Auchus, J. D. de Bono, 2012, The Journal of clinical endocrinology and metabolism.

Prospective study of oncogenic mutations in circulating cell-free DNA (cfDNA) using a multiplex sequencing platform for patient (pt) allocation to phase I clinical trials.

J. Bono, U. Banerji, S. Kaye, 2012 .

A HIF-Regulated VHL-PTP1B-Src Signaling Axis Identifies a Therapeutic Target in Renal Cell Carcinoma

B. Al-Lazikani, D. Qian, H. Moch, 2011, Science Translational Medicine.

Design and rationale of the "Sedation strategy and cognitive outcome after critical illness in early childhood" study.

D. Angus, D. Wypij, S. Beers, 2018, Contemporary clinical trials.

Visuospatial Processing De fi cits Linked to Posterior Brain Regions in Premanifest and Early Stage Huntington ’ s Disease

C. Frost, S. Tabrizi, B. Leavitt, 2017 .

Visuospatial Processing Deficits Linked to Posterior Brain Regions in Premanifest and Early Stage Huntington’s Disease

C. Frost, S. Tabrizi, B. Leavitt, 2016, Journal of the International Neuropsychological Society.

Multi-Purpose Utility of Circulating Plasma DNA Testing in Patients with Advanced Cancers

U. Banerji, S. Kaye, T. Yap, 2012, PloS one.

Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?

J. Bono, D. Olmos, J. D. de Bono, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.